Provided By GlobeNewswire
Last update: Aug 14, 2025
Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5% royalty on future net sales of UNLOXCYTâ„¢ (cosibelimab-ipdl)
Read more at globenewswire.comFORTRESS BIOTECH INC - FBIO 9 3/8 PERP
NASDAQ:FBIOP (8/15/2025, 8:18:30 PM)
7.88
+0.73 (+10.21%)
2.12
+0.16 (+8.16%)
Find more stocks in the Stock Screener